argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

Tuesday, December 13, 2016 1 min read

Key Takeaway: argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

Full Press Release Details

argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients.